SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment
Tuesday, January 11, 2005 BiopharmaWatch Research 1 min read
Key Takeaway: SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment.